67 results about "Open angle glaucoma" patented technology

A system for non-invasive treatment of a patient's trabecular meshwork to treat primary open-angle glaucoma. The system and technique applies energy directly to media within clogged spaces in a patient's trabecular meshwork to increase aqueous outflow facility by (i) localization of microimplantable bodies carrying a selected exogenous chromophore, such as particles with a gold surface, in deeper regions of the trabecular meshwork, and (ii) irradiation of the microimplantables with a selected coherent wavelength having a power level and pulse duration that is strongly absorbed by the surfaces of the microimplantables.

Presbyopia is treated by implanting within a plurality of elongated pockets formed in the tissue of the sclera of the eye transverse to a meridian of the eye, a prosthesis having an elongated body having a first surface and a second surface opposite the first surface to contact the base and flap of the scleral pocket. The first and second surfaces are spaced apart a distance so that the implanted prosthesis exerts an outward force on the flap of the scleral pocket which results in an outward traction on at least the anterior margin of the scleral pocket. The combined effect of the implanted prostheses is to exert a radially outward traction on the sclera in the region overlying the ciliary body which expands the sclera in the affected region together with the underlying ciliary body. The expansion of the ciliary body restores the effective working distance of the ciliary muscle in the presbyopic eye and thereby increases the amplitude of accommodation. Hyperopia, primary open angle glaucoma and / or ocular hypertension can be treated by increasing the effective working distance of the ciliary muscle according to the invention. A preferred embodiment of the scleral prosthesis has a major surface adapted to contact the base or flap of the pocket and an opposite surface or ridge spaced from the major surface.

Presbyopia is treated by implanting within a plurality of elongated pockets formed in the tissue of the sclera of the eye transverse to a meridian of the eye, a prosthesis having an elongated base member having an inward surface adapted to be placed against the inward wall of the pocket and having a ridge on the inward surface of the base extending along at least a major portion of the major dimension of the base. The combined effect of the implanted prostheses is to exert a radially outward traction on the sclera in the region overlying the ciliary body which expands the sclera in the affected region together with the underlying ciliary body. The expansion of the ciliary body restores the effective working distance of the ciliary muscle in the presbyopic eye and thereby increases the amplitude of accommodation. Hyperopia, primary open angle glaucoma and / or ocular hypertension can be treated by increasing the effective working distance of the ciliary muscle according to the invention.

Embodiments include methods, apparatuses, and systems for reducing elevated intraocular pressure (IOP) in a patient to either prevent or treat open-angle glaucoma. Heat is applied to the trabecular meshwork in the patient's eye without damaging proteins in the trabecular meshwork. The application of heat to the trabecular meshwork has the effect of relaxing or loosening protein clogs or other inhibitors in the trabecular meshwork, which are either reducing or obstructing of the outflow of aqueous humor, thereby increasing the patient's IOP and causing ocular hypertension (OHT). By loosening or relaxing clogs or other inhibitors in the trabecular meshwork, the outflow path for aqueous humor is increased or restored, which can lower IOP and either prevent or treat glaucoma. Force may also be applied to the patient's eye to apply pressure to the trabecular meshwork to further assist in the loosening or relaxing of clogs or other inhibitors in the trabecular meshwork.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred IOP-lowering agents are angiostatic steroids, particularly anecortave acetate, and the most preferred route of administration is an anterior juxtascleral injection or implant. The invention is based in part on the discovery that anterior juxtascleral injections of anecortave acetate are capable of controlling intraocular pressure for sustained periods of from one to several months or more. This result is believed to be attributable to facilitation of access of the anecortave acetate to the trabecular meshwork via the anterior juxtascleral route of administration. This route of administration is also believed to be advantageous for other types of IOP-lowering agents, particularly molecules that cannot readily penetrate the cornea due to size or other physical properties.

The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions.

Embodiments include methods, apparatuses, and systems for reducing elevated intraocular pressure (IOP) in a patient to either prevent or treat open-angle glaucoma. Heat is applied to the trabecular meshwork in the patient's eye without damaging proteins in the trabecular meshwork. The application of heat to the trabecular meshwork has the effect of relaxing or loosening protein clogs or other inhibitors in the trabecular meshwork, which are either reducing or obstructing of the outflow of aqueous humor, thereby increasing the patient's IOP and causing ocular hypertension (OHT). By loosening or relaxing clogs or other inhibitors in the trabecular meshwork, the outflow path for aqueous humor is increased or restored, which can lower IOP and either prevent or treat glaucoma. Force may also be applied to the patient's eye to apply pressure to the trabecular meshwork to further assist in the loosening or relaxing of clogs or other inhibitors in the trabecular meshwork.

The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions.

This invention relates to synthetic bifunctional compounds comprising a first rho-associated kinase (ROCK) inhibiting compound and a second pharmaceutically active compound with complementary activity; the first and the second compounds are covalently linked by a biologically labile bond. This invention also relates to methods of making such compounds. The invention also relates to methods of using such bifunctional compounds in the prevention or treatment of diseases or conditions that are affected or can be assisted by altering the integrity or rearrangement of the cytoskeleton. Particularly, this invention relates to methods of treating ophthalmic diseases such as disorders in which intraocular pressure is elevated, for example primary open-angle glaucoma, using the bifunctional compounds.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

A method and clip for treating presbyopia and / or open angle glaucoma in which the sclera is supported or reinforced, while substantially maintaining the special relationship between the ciliary muscle and the lens. The method includes making an incision in the conjunctiva to gain access to the sclera overlying the ciliary muscle. The Tenon's capsules are moved laterally to expose the sclera, and opposed shallow pockets are made in the sclera. A clip, or series of clips, is provided having two opposed feet, which are received in the opposed pockets in the sclera. The Tenon's capsules are then slid over the clip and the conjunctiva is closed.

A method and clip for treating presbyopia and / or open angle glaucoma in which the sclera is supported or reinforced, while substantially maintaining the special relationship between the ciliary muscle and the lens. The method includes making an incision in the conjunctiva to gain access to the sclera overlying the ciliary muscle. The Tenon's capsules are moved laterally to expose the sclera, and opposed shallow pockets are made in the sclera. A clip, or series of clips, is provided having two opposed feet, which are received in the opposed pockets in the sclera. The Tenon's capsules are then slid over the clip and the conjunctiva is closed.

The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema.

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through an upper punctum and into an upper lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a lower punctum and into a lower lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

The present invention relates to an intelligent screening system suitable for high myopia complicated by open angle glaucoma and an establishment method thereof. The system is based on repeated testing, adjustment and training of clinical data of a large number of high myopia patients, learns to identify and evaluate optic disc morphology, thickness of a retinal nerve fiber layer of each quadrant,and thickness of macular ganglion cell complex from a glaucoma OCT examination, evaluates visual field defect degrees from a visual field examination, identifies and evaluates optic disc tilt, opticdisc rotation degrees and beta-area atrophy degrees from eye ground photo images, and then synthesizes patients' basic information, intraocular pressure, spherical power, corneal thickness, axis oculiand other indexes to form comprehensive screening results. Clinicians provide relevant clinical data to the system. The system can quickly and accurately screen out patients with high myopia complicated by open angle glaucoma or gives a risk assessment and provides basis for early detection by doctors and early prevention of the high myopia complicated by open angle glaucoma.

The invention relates to compounds capable of inhibiting the visual cycle and / or dark adaptation and their use for treatment and prevention of non-degenerative retinal diseases with specific emphasis on the prevention and treatment of diabetic retinopathy, retinopathy of prematurity, branch retinal vein occlusion, central retinal vein occlusion, open-angle glaucoma, veovascular glaucoma, and other diseases of the retinal and / or optic nerve where an imbalance between metabolic demand and blood supply contribute to the development of tissue damage. The invention furthermore relates to pharmaceutical compositions comprising such compounds.

The invention discloses a miniature glaucoma drainage implant device and system. The implant system comprises an implant device and an implant made of materials which are good in biocompatibility. The miniature glaucoma drainage implant device and system can be used for open-angle glaucoma as well as goniosynechialysis glaucoma. The surgery that the implant device is utilized to implant the implant is simple, bulbar conjunctiva does not need to be opened, damage to the eye tissues is small, and thus a possibly caused fibrosis reaction is correspondingly reduced.

RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; beta1- and beta2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na-K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

The invention discloses a disease gene animal model of primary open angle glaucoma and a construction method thereof. The method comprises the following steps: (1) cloning human an OPTN (optineurin, E50K) mutant gene to an expression vector with a retinal specific promoter c-kit to construct a recombinant mammal expression vector; and (2) introducing the recombinant mammal expression vector into the bodies of mice and screening and identifying to obtain transgenic mice. In consideration of the difference between the mouse OPTN (E50K) and the human gene, the human OPTN (E50K) is introduced into the retinal specific promoter so that the human OPTN (E50K) gene is specifically expressed in the retina of the mouse. The model of primary open angle glaucoma due to the mutation of OPTN (E50K) is constructed, and the laboratory animals are provided for the systemic researches on pathogenic mechanism, development trend and disease prognosis and treatment of primary open angle glaucoma (POAG) due to the mutation of OPTN (E50K) in human beings.

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through an upper punctum and into an upper lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a lower punctum and into a lower lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

The invention relates to an application of miR-1 in production of a preparation for treating primary glaucoma, an application of miR-1 in production of a reagent for inhibiting cell proliferation of human eye trabecular meshwork cells, an application of miR-1 in production of a reagent for inhibiting adhesion of human eye trabecular meshwork cells, an application of miR-1 in production of a reagent for enhancing migration capacity of human eye trabecular meshwork cells and an application of miR-1 in production of a reagent for inhibiting expression level of fibronectin in human eye trabecular meshwork cells. According to the invention, the regulation effects of miR-1 on the proliferation, migration and adhesion functions of the trabecular meshwork cells are proved on the basis of observing the expression condition of miR-1 in the trabecular meshwork cells under an oxidative stress state, and the targeting of miR-1 on FN (fibronectin) is further confirmed, and the treatment value of miR-1 on POAG (primary open angle glaucoma) is confirmed.

The present invention relates to a Chinese medicine Xiongdan Kaiming tablet with the functions of purging the liver of pathogenic fire, nourishing yin and improving acuity of sight for curing the diseases of conjunctival congestion, blurred vision, red and dry eyes, unclear vision, acute iridocyclitis and primary open-angle glaucoma, etc. with obvious therapeutic effect. Said Chinese medicine Xiongdan Kaiming tablet is made up by using 8 Chinese medicinal materials of bear gall powder, abalone shell, chrysanthemum flower, calcined abalone shell, lyceum berry, prepared olisma tuber and others through traditional Chinese medicine preparation process.

Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred IOP-lowering agents are angiostatic steroids, particularly anecortave acetate, and the most preferred route of administration is an anterior juxtascleral injection or implant. The invention is based in part on the discovery that anterior juxtascleral injections of anecortave acetate are capable of controlling intraocular pressure for sustained periods of from one to several months or more. This result is believed to be attributable to facilitation of access of the anecortave acetate to the trabecular meshwork via the anterior juxtascleral route of administration. This route of administration is also believed to be advantageous for other types of IOP-lowering agents, particularly molecules that cannot readily penetrate the cornea due to size or other physical properties.

The present invention provides a RNA interference for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; beta1- and beta2 adrenergic receptors; acetylcholinesterase; Na<+> / K<+>-ATPase; and Na-K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

The glucomatous trabecula resection filling drainage device is applicable to non-penetrating trabecula resection therapy of open-angle glaucoma and penetrating trabecula resection therapy is acute and chronic angle-closure glaucoma. Said filling drainage device is made up by using hydrophilic acrylic biological material, the length of every direction is 3-5 mm, and thickness is 0.5-0.5mm. In the course of operation said filling drainage device is implanted in the "lake" of sclera or decompression cabin, and can effectively prevent aqueous human channel new-made after operation from producing inflammation and cicatrization, and retain continuous existence of functional liquid cavity, promote outflow of aqueous humor and ensure success of operation. As compared with existent sodium hyaluronate filling material its cost can be reduced by above 80%.